Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanoliposomal Irinotecan in Refractory High Grade Neuroendocrine Cancer
NCT03736720Phase 2Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jun 2019
- Primary completion
- Oct 2022
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoliposomal irinotecan in neuroendocrine carcinoma (NEC), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Objective Response Rate at 6 months. Started Jun 2019; status: terminated.
02
Drugs
nanoliposomal irinotecan
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT03736720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03736720.